IMPORTANCE Anecdotal evidence suggests that deep brain stimulation (DBS) of the internal globus pallidus (GPi) is effective in ameliorating dystonia in X-linked dystonia parkinsonism (XDP), a disease that is usually refractive to medical therapy.
X -linked dystonia parkinsonism (XDP) is a neurodegenerative movement disorder that affects mostly Filipino men owing to the X-linked recessive inheritance of a founder mutation in the TATA box-binding proteinassociated factor 1 (TAF1) gene region.
1,2 X-linked dystonia parkinsonism is characterized by adult-onset focal or segmental dystonia, which rapidly generalizes within a few years. In most patients, dystonic symptoms become less severe and overlap or are replaced with parkinsonian features 5 to 10 years after disease onset. 3 Postmortem investigations identified a loss of striatal medium spiny neurons predominantly in the striosomal compartment, which resulted in striking striatal atrophy. [4] [5] [6] [7] Dystonia in XDP is severe and results in immobility, pain, insufficient food intake, weight loss, and aspiration, and oral treatments with antidystonic drugs are largely ineffective.
8 Deep brain stimulation of the internal pallidum (GPi-DBS) is an established therapeutic option in patients with treatment-refractory generalized and segmental-isolated dystonia 9 and has successfully been used in individual patients with XDP, providing anecdotal evidence only. 10, 11 In this study, we prospectively determined the association of bilateral GPi DBS in 16 patients with XDP and combined clinical examinations with neuroimaging to identify predictors of postoperative outcome. [1.4] years; range, 1-6 years) with treatment-refractory XDP underwent GPi-DBS at the University Hospital Lübeck (eTable 1 and eMethods 1 in the Supplement). A multimodal research study accompanied the DBS procedure and was approved by the ethics committee of the University of Lübeck (AZ12-219). Before participation, informed written consent was obtained from all participants. Informed consent forms were translated to and explained in Tagalog, the official Filipino language.
Methods

Participants
Clinical Assessment
The primary outcome measure of this prospective study was the improvement of dystonia and parkinsonism after GPi-DBS. For dystonia, the motor part of the Burke-FahnMarsden scale (BFMDRS-M) was used, whereas parkinsonism was assessed with the Unified Parkinson's Disease Rating Scale part III (UPDRS-III). As tremor at rest is more common in parkinsonism than dystonia, a UPDRS-III subscore that focused on rest tremor as a cardinal parkinsonian sign was obtained to determine the response of a more specific parkinsonian feature to DBS ( 
Statistical Analysis
For the masked video rating, the means of the 2 observermasked scores were compared at the preoperative, 1-week, and 6-month points using a 1-way analysis of covariance (ANOVA) with Tukey post hoc tests. Two videos were not available. A repeated-measures ANOVA was done for the scores that were obtained during the unmasked long-term follow-up examinations, taking into account 6 points. A Greenhouse-Geyser correction was applied in case that the sphericity had been violated using the Mauchly test. Subsequently, Tukey post hoc tests were performed and the mean of each column was compared with the mean of every other column. Secondary end points were compared using paired t tests; for HADS, MoCA, FAB, TMT A, TMT B, weight, and SF-36 domains, tests were done between the preoperative and postoperative periods between months 6 and 26. The statistical analysis for the remaining scores was carried out between preoperative and 6 months because the primary end point of motor improvement was assessed after 6 months. For categorial variables, χ 2 tests were performed. For correlations of behavioral data, the Pearson coefficient was calculated. For correlations of volumetric data, the relative volume of the basal ganglia in association with the total intracranial volume was used. Values of <.05 were considered significant except for analyses in which correction for multiple testing was done. When applicable, tests were done 2-sided. GraphPad Prism, version 7 (La Jolla) was used. Values are presented as mean (SD). Meaning Pallidal DBS should be considered a first-line treatment in medically intractable X-linked dystonia parkinsonism, and given the association of poorer treatment outcomes in patients with more advanced neurodegeneration, DBS should potentially be considered during the earlier stages of the disease.
Key Points
Results
The preoperative BFMDRS-M score of 58.1 (SD, 16.8; range 33-88) indicated severe dystonia in the cohort (Table) . The mean (SD) UPDRS-III score was 38.9 (14.1; range 18-59). Twelve patients had a dystonia-predominant phenotype (XDP-D) whereas 4 patients clearly had additional significant parkinsonism (XDP-DP). Thirteen of the 16 operations (81.3%) were performed under general anesthesia because of excessive dystonic movements (eTable 1 in the Supplement). Nonrechargeable pulse generators were implanted (St. Jude Libra XP; electrode 6143; n = 10 [62.5%]; Medtronic Activa PC, electrode 3387; n = 6 [37.5%]).
Masked Video Ratings
Dystonia improved significantly following bilateral GPi-DBS (F 2,26 = 14.32; P < .001; n = 14 [87.5%]). The mean reduction on the BFMDRS scale was 55% at 1 week (range, −94% to 59%; P < .01) and 59% at 6 months (range, −100% to 22%; P < .001) after surgery ( Figure 1 , Videos 1, 2, and 3). There was a main association of DBS with the UPDRS-III score postoperatively (F 2, 26 = 4.51; P = .02). Post hoc tests for single points were significant at 6 weeks only (1 week, 19% reduction; P = .12; 6 months, 27% reduction; P = .002) ( Figure 1B ). There were no significant differences between observations at 1 week and 6 months, respectively (BFMDRS-M, P =. 95; UPDRS-III, P = .65).
Long-term Follow-up Examination
The repeated-measures ANOVA revealed a significant reduction of the BFMDRS-M (F 5,45 =27 .3;P < .001) and a significant association with the UPDRS-III score (F 5,30 = 7.23; P = .015 [Greenhouse-Geyser corrected]) (Figure 1 ; Table) . In regard to dystonia, the post hoc analysis showed significant differences between preoperative BFMDRS-M scores compared with any postoperative point. Significant differences were also observed when comparing BFMDRS scores 1 week postoperatively with those at 3 months, 3 months and last follow-up, and 6 months and last follow-up.
The post hoc analysis of the UPDRS-III demonstrated differences between preoperative scores compared with 3 months and 6 months and between 1 week and 6 months and 12 months postoperatively. The repeated-measures ANOVA revealed an association of DBS with the UPDRS-III-RT in the subgroup of 5 patients with XDP (31.3%) with a tremor at rest (F 2,30 = 3.55; P =.04) ( Figure 1 ; Video 3). One patient (6.3%) (L-7673) developed parkinsonism following DBS (Video 4). An explorative analysis of single items of the UPDRS (items 29, 30, 31, and 18) and BFMDRS (item 3) revealed an improvement of gait (−54%; P < .001), postural instability (−84%; P < .001), bradykinesia and hypokinesia (−44%; P < .01), speech (−26%; P < .01), and speech and swallowing (−39%; P < .01) 6 months after the operation.
Secondary End Points
The UPDRS-II score had improved by 51% (n = 16 [100%]; P < .001), and the Schwab and England Disability Scale score by 39% (n = 8 [50%]; P < .01) (Table) . Accordingly, most patients were less dependent than before surgery, and some patients regained employment. The scores for severity of illness significantly improved from the patients' (n = 11 [68.75%]; P < .001), caregivers' (n = 10 [62.5%]; P < .001), and physicians' perspective (n = 10 [62.5%]; P < .001). Pain visual analog scale scores decreased by 66% (n = 10 [62.5%]; P < .01). Depressive symptoms as assessed with the HADS score showed a trend toward improvement postoperatively (n = 12 [75%]; P = .05) whereas anxiety remained unchanged (n = 12 [75%]; P > .10) (eTable 2 in the Supplement). Four domains that were associated with quality of life (SF-36) improved after surgery (eTable 2 in the Supplement). Cognitive scores, including MoCA, FAB, and TMT A and B, remained unchanged after DBS.
Adverse events and stimulator settings are listed as eResults and the eTable 3 in the Supplement. Surgery-related adverse events occurred in 6 of 16 patients (37.5%) and included 2 asymptomatic intracerebral hemorrhages and 3 hematomas at the site of the pulse generator. All adverse events resolved without sequelae. 
Basal Ganglia Volumetry
There was a high association between the volume of the caudate nucleus but not of the putamen or the globus pallidus with postoperative BFMDRS-M improvement 6 months after surgery (r = 0.817; P = .004), indicating that DBS was less effective in patients with a more pronounced caudate atrophy ( Figure 2) . No correlations were detected with regard to changes in the UPDRS-III score. There was also no association between caudate atrophy and preoperative dystonia severity (BFMDRS-M), severity of parkinsonism (UPDRS-III), and global cognitive function (MoCA) (P values between .17 and .97).
Discussion
To our knowledge, this is the first prospective and long-term follow-up study describing the efficacy and safety of GPi-DBS in patients with severe XDP and predominant dystonia. Deep brain stimulation led to a remarkable and long-lasting improvement of dystonia. 10,11 Notably, motor functions improved rapidly within a few days postoperatively, which was sustained during the follow-up period, such as in DYT1 dystonia. 12 In this regard, we observed a microlesion effect in some of the patients but stimulation had a clear additional association. Over the long-term course of the study, there was a slightly diminishing effect on the control of dystonia, which likely indicated disease progression given that the stimulation parameters were reviewed regularly and adjusted if necessary. As secondary outcome measures, disabling pain contributing to a reduced quality of life preoperatively was also markedly ameliorated and depressive symptoms showed a trend toward improvement. The improvement of quality of life of 67% on average across the different domains was at least comparable with most other studies in which improvement was 50% at the most. 13 Unlike potential deterioration in patients with Parkinson disease undergoing subthalamic nucleus DBS, global cognitive functions were unchanged after GPi-DBS in our sample, which is an important safety measure. The observed bleeding complications, including 2 small asymptomatic intracerebral hemorrhages, resolved without sequelae. The reasons are speculative but the preoperative nutritional status and disease-related effects may have contributed to these adverse 
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Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism events. In the previously published case reports, intracranial hemorrhage was not mentioned as a frequent adverse event; therefore, this complication may just have incidentally occurred in the patients in this study. Atrophy of the caudate nucleus was associated with a less beneficial response of motor symptoms to DBS, which indicated that this surgical intervention may be more favorable when neurodegeneration is less advanced. Caudate atrophy was not associated with preoperative disease severity, which argues for a specific interaction of atrophy and the ability of DBS to alleviate dystonic symptoms. In other types of dystonias, no such structural surrogate markers have been identified as most forms of dystonia are not accompanied by neurodegenerative changes. However, several studies indicate that early DBS in severe dystonia is a predictor for a beneficial postoperative outcome.
12,14,15
Limitations
The variability of response to DBS was considerably higher for the UPDRS-III score compared with the BFMDRS-M score, in keeping with the notion that the assessment of parkinsonism in a combined dystonia parkinsonism syndrome poses a major clinical challenge. In response to this, recently a dedicated rating scale was developed and validated in 204 patients with XDP, but it was not yet available for this study. 16 Because nonrechargeable DBS batteries were implanted initially, it was expected that the symptomatic effect of neurostimulation would last for a limited time only. In anticipation of this problem, we applied for further funding, allowing for subsequent battery replacement.
Conclusions
Internal global pallidus DBS should be considered as a first-line treatment in medically intractable XDP. Because advanced neurodegeneration was associated with a poorer response, DBS should be considered during the early stages of the disease. Close collaboration, trust-based relationships, continuous education, and multiple-source funding (eDiscussion in the Supplement) were mainstays of success for the project, which may serve as a model from which to embark on complex clinical interventions in resource-challenged settings. Six patients with implanted DBS leads (2 Activa PC, 4 Libra XP) were erroneously subjected to MRI scanning in the course of local F/U. This procedure was initiated by one member of the local study group and was neither communicated with the remainder of the Filipino study group nor with the German PIs. The patients underwent structural 1.5T MRI in Manila with the pulse generators switched on during the scan. After the MRI, the clinical status and DBS pulse generator function was unaltered in one patient (1 Activa PC, 0 Libra XP). Four patients equipped with a Libra XDP, however, deteriorated immediately after the scan with regard to dystonia. Several reprogramming approaches were undertaken and succeeded in an improvement of dystonia that was approximately at a level of 80% compared to the pre-MRI status.
eDiscussion: Medical care, capacity building and follow-up
The current study imposed high demands on the interaction between medical professionals on two continents. Patient selection and F/U care was carried out by the medical team in the Philippines, whereas the surgery, perioperative care as well as initial stimulator programming were performed in Germany. Further, standardized F/U examinations were guaranteed through a jointly developed protocol. Another benefit of the study was capacity building in the Philippines through practical DBS and programming skills, along with sustainability of the treatment for the patients and their families.
As non-rechargeable DBS batteries were implanted initially, it was expected that the symptomatic effect of neurostimulation would last for a limited time only. In anticipation of this problem, we applied for further funding, allowing subsequent battery replacement. The transient dystonic phase of XDP is the major source of suffering for most patients; thus, DBS in this phase helps patients overcome severely disabling symptoms during the most vulnerable disease period. Regarding the important aspect of sustainability and extension of GPi-DBS for XDP patients, our relatively small project has also served to build a base for first discussions with Filipino governmental health authorities aiming to include XDP into a national rare disease program. All patients were operated outside of the Philippines. 
